On May 27, 2020, Gilead Sciences and Arcus Biosciences announced that the companies had entered into a 10-year partnership to co-develop and co-commercialize current and future therapeutic product candidates in Arcus’s pipeline. The agreement will also provide ongoing funding to support Arcus’s research and development programs.